Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675436 | 0.88 | GPR119 (0.45) | GPR119 | |
| SCHEMBL10090890 | 0.88 | RBP4 (0.37) | GPR119RBP4 | |
| SCHEMBL2675233 | 0.84 | GPR119 (0.42) | GPR119USP30POLB | |
| SCHEMBL30785512 | 0.83 | HDAC4 (0.41) | GPR119USP30RBP4POLB | |
| SCHEMBL27158244 | 0.83 | HDAC4 (0.41) | GPR119USP30RBP4POLB | |
| SCHEMBL586621 | 0.77 | SLC6A2 (0.45) | GPR119 | |
| SCHEMBL29912864 | 0.77 | GPR119 (0.47) | GPR119ALOX5APFEN1USP30RBP4 | |
| SCHEMBL27158392 | 0.77 | GPR119 (0.47) | GPR119ALOX5APFEN1USP30RBP4 | |
| SCHEMBL590425 | 0.76 | SLC6A2 (0.41) | GPR119POLB | |
| SCHEMBL10090874 | 0.76 | SLC6A2 (0.41) | GPR119POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173821-B2 | Serotonin and norepinephrine reuptake inhibitor | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173821-B2 | Serotonin and norepinephrine reuptake inhibitor | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2010117979-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | SLC6A2, SLC6A4, TPH1 | GPR119 708/4885ALOX5AP 927/4885FEN1 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.